Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

PD-1 Protein (AA 25-167) (His tag)

This Recombinant PD-1 protein is expressed in HEK-293 Cells and has been mentioned in 4+ publications.
Catalog No. ABIN2181605

Quick Overview for PD-1 Protein (AA 25-167) (His tag) (ABIN2181605)

Target

See all PD-1 (PDCD1) Proteins
PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Protein Type

Recombinant

Biological Activity

Active

Origin

  • 40
  • 14
  • 6
  • 4
  • 4
  • 3
  • 1
Human

Source

  • 50
  • 5
  • 5
  • 3
  • 3
  • 3
  • 2
  • 1
HEK-293 Cells

Purity

>95 % as determined by SDS-PAGE.

Grade

HPLC verified
  • Protein Characteristics

    AA 25-167

    Purification tag / Conjugate

    This PD-1 protein is labelled with His tag.

    Sequence

    AA 25-167

    Characteristics

    This protein carries a polyhistidine tag at the C-terminus, and has a calculated MW of 16.77 kDa. The N-terminus Sequence Analysis is Leu 25. The reducing (R) protein migrates as 25-45 kDa in SDS-PAGE due to glycosylation.

    Sterility

    0.22 μm filtered

    Endotoxin Level

    Less than 1.0 EU per μg by the LAL method.
  • Want other Options for this Protein ?

    !
    Discover Our Predefined Custom Proteins and Custom Protein Services!

    Your project requires further customization? Contact us and discover our custom protein solutions

  • Restrictions

    For Research Use only
  • Format

    Lyophilized

    Buffer

    PBS, pH 7.4

    Handling Advice

    Please avoid repeated freeze-thaw cycles.

    Storage

    -20 °C

    Storage Comment

    No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
  • Assi, Wong, Tipton, Mei, Wong, Razo, Chan, Howng, Sagert, Krimm, Diep, Jang, Nguyen, Lapuyade, Singson, Villanueva, Paidhungat, Liu, Rangan, Vasiljeva, West, Richardson, Irving, Daniel, Belvin et al.: "Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. ..." in: Cancer immunology research, Vol. 9, Issue 12, pp. 1451-1464, (2022) (PubMed).

    Curnock, Bossi, Kumaran, Bawden, Figueiredo, Tawar, Wiseman, Henderson, Hoong, Gonzalez, Ghadbane, Knight, ODwyer, Overton, Lucato, Smith, Reis, Page, Whaley, McCully, Hearty, Mahon, Weber: "Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors." in: JCI insight, Vol. 6, Issue 20, (2021) (PubMed).

    Wang, Fei, Jing, Wu, Wu, Zhou, Ni, Chen, Xiong, Liu, Peng, Yu, Jiang, Liu: "Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit." in: mAbs, (2019) (PubMed).

    Boohaker, Sambandam, Segura, Miller, Suto, Xu: "Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction." in: Cancer letters, Vol. 434, pp. 11-21, (2018) (PubMed).

  • Target

    PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

    Alternative Name

    PD-1

    Background

    Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

    Molecular Weight

    16.8 kDa

    NCBI Accession

    NP_005009

    Pathways

    Cancer Immune Checkpoints
You are here:
Chat with us!